Suchergebnisse - "Kumar, Shaji"

PubPharm (1.159)

1

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma

enthalten in: BMC cancer | 2024

von Dimopoulos, M. | Sonneveld, P. | Manier, S. | +10

2

Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma.

enthalten in: ResearchSquare.com | 2024

von Kumar, S. | Rees, M. | Mammadzadeh, A. | +20

3

Thromboprophylaxis in multiple myeloma : a case-based review with practical guidelines

enthalten in: Annals of hematology | 2024

von Charalampous, C. | Shah, D. | Kumar, S. | +1

4

Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data

enthalten in: Advances in therapy | 2024

von Durie, B. | Kumar, S. | Ammann, E. | +5

5

An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Alodhaibi, I. | Ailawadhi, S. | Burbano, G. | +5

6

High-risk multiple myeloma : Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy

enthalten in: American journal of hematology | 2024

von Rees, M. | Kumar, S.

7

Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

enthalten in: Leukemia | 2024

von Zanwar, S. | Gertz, M. | Muchtar, E. | +19

8

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

enthalten in: Blood cancer journal | 2024

von Goel, U. | Charalampous, C. | Kapoor, P. | +18

9

Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data

enthalten in: Advances in therapy | 2024

von Durie, B. | Kumar, S. | Ammann, E. | +5

10

Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Goldman-Mazur, S. | Visram, A. | Rajkumar, S. | +14

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[116]